The stock of Amgen, Inc. (NASDAQ:AMGN) is a huge mover today! About 779,263 shares traded hands. Amgen, Inc. (NASDAQ:AMGN) has declined 10.92% since April 26, 2016 and is downtrending. It has underperformed by 16.18% the S&P500.
The move comes after 5 months positive chart setup for the $108.73 billion company. It was reported on Nov, 29 by Barchart.com. We have $153.85 PT which if reached, will make NASDAQ:AMGN worth $5.44 billion more.
Analysts await Amgen, Inc. (NASDAQ:AMGN) to report earnings on January, 26. They expect $2.77 EPS, up 6.13% or $0.16 from last year’s $2.61 per share. AMGN’s profit will be $2.06B for 13.22 P/E if the $2.77 EPS becomes a reality. After $3.02 actual EPS reported by Amgen, Inc. for the previous quarter, Wall Street now forecasts -8.28% negative EPS growth.
Amgen, Inc. (NASDAQ:AMGN) Ratings Coverage
Out of 17 analysts covering Amgen Inc. (NASDAQ:AMGN), 10 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 59% are positive. Amgen Inc. has been the topic of 29 analyst reports since August 3, 2015 according to StockzIntelligence Inc. Citigroup maintained it with “Neutral” rating and $175 target price in Friday, July 29 report. The stock of Amgen, Inc. (NASDAQ:AMGN) has “Buy” rating given on Monday, September 7 by UBS. The firm has “Market Perform” rating given on Friday, December 4 by Wells Fargo. The stock of Amgen, Inc. (NASDAQ:AMGN) has “Outperform” rating given on Friday, July 31 by RBC Capital Markets. Citigroup initiated the shares of AMGN in a report on Thursday, February 25 with “Neutral” rating. Mizuho initiated Amgen, Inc. (NASDAQ:AMGN) rating on Tuesday, November 8. Mizuho has “Buy” rating and $164 price target. Bernstein initiated the shares of AMGN in a report on Wednesday, June 29 with “Market Perform” rating. Piper Jaffray maintained Amgen, Inc. (NASDAQ:AMGN) on Saturday, August 29 with “Overweight” rating. UBS maintained Amgen, Inc. (NASDAQ:AMGN) rating on Thursday, October 29. UBS has “Buy” rating and $180 price target. As per Tuesday, September 1, the company rating was initiated by Raymond James.
According to Zacks Investment Research, “Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.”
Insitutional Activity: The institutional sentiment decreased to 1.26 in Q2 2016. Its down 0.02, from 1.28 in 2016Q1. The ratio fall, as 56 funds sold all Amgen, Inc. shares owned while 422 reduced positions. 77 funds bought stakes while 533 increased positions. They now own 577.82 million shares or 7.76% less from 626.39 million shares in 2016Q1.
D E Shaw And Com has invested 0.47% of its portfolio in Amgen, Inc. (NASDAQ:AMGN). Jane Street Group Ltd Liability Company has 25,752 shares for 0.02% of their US portfolio. Grantham Mayo Van Otterloo Co Ltd Company owns 2,799 shares or 0% of their US portfolio. Essex Service holds 1.95% of its portfolio in Amgen, Inc. (NASDAQ:AMGN) for 53,024 shares. The California-based California Employees Retirement has invested 0.48% in Amgen, Inc. (NASDAQ:AMGN). Kcm Inv Advisors Ltd accumulated 0.17% or 16,031 shares. Polaris Greystone Group Limited Company, a California-based fund reported 1,701 shares. Moreover, Credit Agricole S A has 0.55% invested in Amgen, Inc. (NASDAQ:AMGN) for 942,366 shares. Moreover, Motley Fool Wealth Limited Co has 0.03% invested in Amgen, Inc. (NASDAQ:AMGN) for 2,032 shares. The United Kingdom-based Uss Invest has invested 0.18% in Amgen, Inc. (NASDAQ:AMGN). Bokf Na accumulated 46,437 shares or 0.25% of the stock. Umb Retail Bank N A Mo owns 98,730 shares or 0.63% of their US portfolio. Amg Natl Bankshares accumulated 8,735 shares or 0.12% of the stock. Bowling Ltd Liability reported 62,462 shares or 1.55% of all its holdings. Pineno Levin And Ford Asset Mgmt Inc accumulated 0.14% or 1,798 shares.
Insider Transactions: Since August 1, 2016, the stock had 0 buys, and 1 sale for $523,758 net activity. $523,758 worth of Amgen, Inc. (NASDAQ:AMGN) was sold by Such Annette Louise.
More notable recent Amgen, Inc. (NASDAQ:AMGN) news were published by: Forbes.com which released: “Why Amgen is the ‘Top Dividend Stock of the Nasdaq 100’ With 2.8% Yield (AMGN)” on November 28, 2016, also Seekingalpha.com with their article: “Amgen: Enbrel Is Undervalued” published on November 29, 2016, Fool.com published: “Better Buy: Amgen Inc. vs. Johnson & Johnson” on November 08, 2016. More interesting news about Amgen, Inc. (NASDAQ:AMGN) were released by: Fool.com and their article: “Why Amgen Inc. Shares Nose-Dived 15.4% in October” published on November 08, 2016 as well as Investorplace.com‘s news article titled: “3 Stocks to Watch on Wednesday: Amgen, Inc. (AMGN), Cisco Systems, Inc. (CSCO …” with publication date: November 17, 2016.
AMGN Company Profile
Amgen Inc., incorporated on October 31, 1986, is a biotechnology company. The Firm discovers, develops, makes and delivers various human therapeutics. The Company’s business segment is human therapeutics. The Company’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Firm focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.